HK1077003A1 - Sustained release formulations comprising lamotrigine - Google Patents

Sustained release formulations comprising lamotrigine

Info

Publication number
HK1077003A1
HK1077003A1 HK05108373.5A HK05108373A HK1077003A1 HK 1077003 A1 HK1077003 A1 HK 1077003A1 HK 05108373 A HK05108373 A HK 05108373A HK 1077003 A1 HK1077003 A1 HK 1077003A1
Authority
HK
Hong Kong
Prior art keywords
lamotrigine
sustained release
release formulations
formulations
sustained
Prior art date
Application number
HK05108373.5A
Other languages
English (en)
Inventor
Ian Richard Buxton
Robin Currie
Myrna A Dela-Cruz
Gary Wayne Goodson
Wlodzimierz Karolak
Mehran Maleki
Vijay Mohan Iyer
Gopal Muppirala
Alan Frank Parr
Jagdev Singh Sidhu
Robert Allen Stagner
Akunuri Venkata Vijay-Kumar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217492A external-priority patent/GB0217492D0/en
Priority claimed from GB0217493A external-priority patent/GB0217493D0/en
Priority claimed from GB0313801A external-priority patent/GB0313801D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1077003A1 publication Critical patent/HK1077003A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK05108373.5A 2002-07-29 2005-09-22 Sustained release formulations comprising lamotrigine HK1077003A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0217492A GB0217492D0 (en) 2002-07-29 2002-07-29 Novel method of treatment
GB0217493A GB0217493D0 (en) 2002-07-29 2002-07-29 Novel methods of treatment
GB0313801A GB0313801D0 (en) 2003-06-13 2003-06-13 Novel methods of treatment
PCT/EP2003/008368 WO2004012741A1 (fr) 2002-07-29 2003-07-28 Formulations a liberation prolongee contenant de la lamotrigine

Publications (1)

Publication Number Publication Date
HK1077003A1 true HK1077003A1 (en) 2006-02-03

Family

ID=31499035

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108373.5A HK1077003A1 (en) 2002-07-29 2005-09-22 Sustained release formulations comprising lamotrigine

Country Status (29)

Country Link
US (1) US20050032799A1 (fr)
EP (1) EP1524981B1 (fr)
JP (2) JP4744142B2 (fr)
KR (1) KR100882707B1 (fr)
CN (1) CN100363007C (fr)
AR (1) AR040709A1 (fr)
AT (1) ATE424827T1 (fr)
AU (1) AU2003260336C1 (fr)
BR (1) BRPI0313148B8 (fr)
CA (1) CA2493301A1 (fr)
CO (1) CO5680405A2 (fr)
CY (1) CY1109119T1 (fr)
DE (1) DE60326590D1 (fr)
DK (1) DK1524981T3 (fr)
ES (1) ES2323268T3 (fr)
HK (1) HK1077003A1 (fr)
IL (1) IL166424A (fr)
IS (1) IS2681B (fr)
MA (1) MA27509A1 (fr)
MX (1) MXPA05001243A (fr)
MY (1) MY141049A (fr)
NO (1) NO334221B1 (fr)
NZ (1) NZ537885A (fr)
PL (1) PL213565B1 (fr)
PT (1) PT1524981E (fr)
RU (1) RU2325163C2 (fr)
SI (1) SI1524981T1 (fr)
TW (1) TWI342213B (fr)
WO (1) WO2004012741A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
KR100882707B1 (ko) * 2002-07-29 2009-02-06 글락소 그룹 리미티드 라모트리진을 포함하는 서방형 제제
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
DE602006016934D1 (de) * 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
WO2008109343A1 (fr) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Procédés de traitement des troubles bipolaires et des déficiences de la mémoire et/ou cognitives associées avec ceux-ci avec du (+)-4-(2-chloro-3-cyanophényl)-1,4-dihydro-2,6-diméthylpyridine-3,5-dicarboxylate d'isopropyle et de 2-méthoxyéthyle
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009061513A1 (fr) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Formes cristallines de lamotrigine
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
KR20110052641A (ko) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 변형 방출형 제형 및 이의 이용 방법
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
WO2011086568A1 (fr) * 2010-01-13 2011-07-21 Accutest Research Laboratories (I) Pvt. Ltd Composition à libération contrôlée pour la lamotrigine
MX2013008946A (es) * 2011-02-03 2013-10-25 Lupin Ltd Composiciones farmaceuticas orales de bepotastina de liberacion controlada.
WO2014159275A1 (fr) * 2013-03-14 2014-10-02 PharmTak, Inc. Compositions pharmaceutiques à libération contrôlée comprenant de la lamotrigine et procédés de production de celles-ci
CN103920134A (zh) * 2014-05-08 2014-07-16 崔韡 一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) * 2015-12-21 2017-07-03 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) * 2016-02-18 2017-03-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с пролонгированным высвобождением
BR112019016118A2 (pt) * 2017-02-03 2020-07-14 Jubilant Generics Limited forma farmacêutica de dosagem de suspensão oral de lamotrigina
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Compositions of amantadine, their preparation, and methods of use
US20200318189A1 (en) * 2017-10-27 2020-10-08 Chang Gung Memorial Hospital, Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
CN113214177B (zh) * 2021-04-16 2022-05-03 上海奥科达生物医药科技有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
JPH0667828B2 (ja) * 1985-10-09 1994-08-31 日研化学株式会社 バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
DK0542364T3 (da) * 1991-11-13 1996-03-11 Glaxo Canada Anordning til reguleret frigivelse
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP2001500121A (ja) * 1996-08-23 2001-01-09 アルゴス ファーマシューティカル コーポレーション 神経障害性の痛みを治療する組成物を含む抗けいれん剤
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
US6046716A (en) * 1996-12-19 2000-04-04 Colorado Microdisplay, Inc. Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (fr) * 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
IL142807A0 (en) * 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0024517D0 (en) * 2000-10-06 2000-11-22 Glaxo Group Ltd Use of medicaments
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
KR100882707B1 (ko) * 2002-07-29 2009-02-06 글락소 그룹 리미티드 라모트리진을 포함하는 서방형 제제

Also Published As

Publication number Publication date
JP2005538113A (ja) 2005-12-15
JP2011057683A (ja) 2011-03-24
IS7707A (is) 2005-02-23
MA27509A1 (fr) 2005-09-01
CA2493301A1 (fr) 2004-02-12
MY141049A (en) 2010-02-25
DE60326590D1 (de) 2009-04-23
KR100882707B1 (ko) 2009-02-06
EP1524981A1 (fr) 2005-04-27
WO2004012741A1 (fr) 2004-02-12
BRPI0313148B8 (pt) 2021-05-25
ATE424827T1 (de) 2009-03-15
IL166424A0 (en) 2006-01-15
TW200418484A (en) 2004-10-01
RU2325163C2 (ru) 2008-05-27
CN1681509A (zh) 2005-10-12
JP4744142B2 (ja) 2011-08-10
AR040709A1 (es) 2005-04-13
MXPA05001243A (es) 2005-06-08
NO20050948L (no) 2005-02-22
ES2323268T3 (es) 2009-07-10
CY1109119T1 (el) 2014-07-02
IL166424A (en) 2010-12-30
CO5680405A2 (es) 2006-09-29
PL213565B1 (pl) 2013-03-29
PT1524981E (pt) 2009-06-17
KR20050026054A (ko) 2005-03-14
AU2003260336C1 (en) 2008-05-29
TWI342213B (en) 2011-05-21
EP1524981B1 (fr) 2009-03-11
DK1524981T3 (da) 2009-06-22
PL374982A1 (en) 2005-11-14
BRPI0313148B1 (pt) 2019-08-20
IS2681B (is) 2010-09-15
AU2003260336A1 (en) 2004-02-23
CN100363007C (zh) 2008-01-23
US20050032799A1 (en) 2005-02-10
BR0313148A (pt) 2005-07-12
SI1524981T1 (sl) 2009-08-31
RU2005105353A (ru) 2005-10-27
NO334221B1 (no) 2014-01-13
NZ537885A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
HK1077003A1 (en) Sustained release formulations comprising lamotrigine
EP1537880A4 (fr) Preparation a liberation prolongee
IL159048A0 (en) Sustained release formulation
EP1549296A4 (fr) Preparations a liberation soutenue de metformine
IL162642A0 (en) Formulations
IL165349A0 (en) Microcapsule formulations
EP1383376A4 (fr) Formulations pharmaceutiques a liberation prolongee
EP1552833A4 (fr) Preparations solides stables
HK1058003A1 (en) Sustained release ranolazine formulations
AU2003215334A1 (en) Inhalable formulations for sustained release
AU2003219814A1 (en) Release agents
EP1411904A4 (fr) Composition pharmaceutique a liberation prolongee
AU2003260803A8 (en) Sustained release pharmaceutical composition
GB0323701D0 (en) Formulations
EP1499295A4 (fr) Formulations de metoprolol a liberation prolongee
EP1503804A4 (fr) Formulations radiopharmaceutiques
ZA200500518B (en) Sustained release formulations comprising lamotrigine
IL149014A0 (en) Diamond-cooled solid state lasers
EP1478353A4 (fr) Composition pharmaceutique a liberation soutenue
AU2003241537A8 (en) Biguanide formulations
GB0218194D0 (en) Solid formulations
PL375813A1 (en) Stable topiramate formulations
GB0307765D0 (en) Tissue-adhesive formulations
EP1513505A4 (fr) Preparation a liberation modifiee amelioree
GB0214147D0 (en) Formulations

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230727